HC Wainwright & Co. Reiterates Buy on Aquestive Therapeutics, Maintains $5 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates a Buy rating on Aquestive Therapeutics (NASDAQ:AQST) and maintains a $5 price target.

June 21, 2023 | 11:27 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates a Buy rating on Aquestive Therapeutics and maintains a $5 price target.
The reiterated Buy rating and maintained $5 price target by HC Wainwright & Co. analyst Raghuram Selvaraju on Aquestive Therapeutics (NASDAQ:AQST) is a positive signal for the stock. This reaffirms the analyst's confidence in the company's potential, which could lead to an increase in investor interest and a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100